Beruflich Dokumente
Kultur Dokumente
Phase I Early Years Market share domination by foreign companies Relative absence of organized Indian companies
1970-1980
Phase II Government Control Indian Patent Act 1970 Drug prices capped Local companies begin to make an impact
1980-1990
Phase III Development Phase Process development Production infrastructure creation Export initiatives
1990-2000
Phase IV Growth Phase Rapid expansion of domestic market International market development ResearcAh orientation
2000-2010
EXPORTS:
The pharmaceutical industry is also showing good performance in terms of exports. It has grown at a CAGR of 14% in the last decade. Major export markets include highly regulated markets such as USA, Germany, UK and Canada. Europe is the biggest export destination for Indian pharmaceuticals accounting for more than 30% of the total exports, followed by the Americas region (25%).
Government policies such as Drugs and Cosmetics Act (1940), Drugs Policy (1986), Indian Patents Act (1970), Drug Price Control Order (1995), Pharmaceutical Policy (2002), Indian Patents (Amendment) Act (2005), have played a major role in the growth of Indian pharmaceutical Industry. The Government has also formulated a Draft National Pharmaceutical Policy (2006), which will be finalized after consultation with the stakeholders. Besides, the Government has also facilitated the growth of the Indian pharmaceutical industry through institutional framework and encouraging investments in R&D.
MARKET SEGMENTATION
The Indian government has been making efforts to improve nationwide provision of healthcare. It has launched policies that are aimed at: building more hospitals, boosting local access to healthcare, improving the quality of medical care &training increasing public expenditure on healthcare to 2-3% of GDP, up from a current low of 1%.
Growing middle class with higher purchasing power. Changing disease profile Healthcare Insurance.
SWOT ANALYSIS
STRENGTH
Higher GDP growth Cost competitiveness Low cost, highly skilled set of English speaking labor force Growing treatment nave patient population
WEEKNESS
Poor all-round Infrastructure Stringent price control. Lack of data Protection.
OPPORTUNITIES
Global demand for genetics rising. Rapid OTC & generic market. Increased penetration in the non metro market Increase in health care insurance. Investment from MNCs. PPP for strengthening infrastructure
THREATS
Global demand for genetics rising. Rapid OTC & generic market. Increased penetration in the non metro market Increase in health care insurance. Investment from MNCs. PPP for strengthening infrastructure
Changing paradigm: Indian pharmaceutical industry Revenues from domestic market pharmaceutical revenues in 2006-07 dominated the total
Exports contribution is expected to surpass the domestic turnover by 2010 The pharma sector would witness an upswing in the revenues from service segment due to the increase in outsourcing of Contract research & manufacturing services (CRAMS) to India.
SERVICES- 6.6%
2006 PRODUCTS- 93.4% PHARMACEUTICAL INDUSTRY SERVICES- 12% 2010 PRODUCTS- 88% EXPORT- 62% DOMESTIC- 38% EXPORT- 43% DOMESTIC- 57%
TOP 20 BRANDS